Furthermore, a growing amount of evidence indicated that inactivation of IL1R1 signaling in the experimental models of central nervous system diseases, including multiple sclerosis, Parkinson’s disease, AD, and amyotrophic lateral sclerosis, resulting in decreased neuroinflammation and delayed disease progression [45]. This evidence concerns the gene IL1R1 and Parkinson disease.